Supreme Extends Due Diligence Period

Supreme Pharmaceuticals Inc. (the "Company") (TSX VENTURE:SL)(OTCBB:SPRWF)
reports that the parties have extended the due diligence period in respect to
the Company's peviously announced option agreement for an additional 7 business
days until April 10, 2014. While due diligence results have been positive to
date, the Company requires additional time to ensure the proper assessment of
the South Okanagan producing facility before entering into the option.


President and CEO, David Stadnyk stated: "While we still believe this will be a
positive transaction for the Company and its shareholders, these additional 7
days will give management the appropriate amount of time to make the best
decision for the Company."


SUPREME PHARMACEUTICALS INC.

David Stadnyk, President & CEO 

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term
is defined in policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.


FORWARD LOOKING INFORMATION

This News Release contains forward-looking statements. The use of any of the
words "anticipate", "continue", "estimate", "expect", "may", "will", "project",
"should", "believe" and similar expressions are intended to identify
forward-looking statements. Although the Company believes that the expectations
and assumptions on which the forward-looking statements are based are
reasonable, undue reliance should not be placed on the forward-looking
statements because the Company can give no assurance that they will prove to be
correct. Since forward-looking statements address future events and conditions,
by their very nature they involve inherent risks and uncertainties. These
statements speak only as of the date of this News Release. Actual results could
differ materially from those currently anticipated due to a number of factors
and risks including various risk factors discussed in the Company's disclosure
documents which can be found under the Company's profile on www.sedar.com. This
News Release contains "forward-looking statements" within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E the Securities
Exchange Act of 1934, as amended and such forward-looking statements are made
pursuant to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. 


Listed on the TSX Venture under the symbol ("SL")

FOR FURTHER INFORMATION PLEASE CONTACT: 
Supreme Pharmaceuticals Inc.
#772 Alastair Ross Technology Centre
3553 31st Street NW, Calgary Alberta, T2L 2K7
(647) 340-6744
info@supremepharmaceuticals.com
www.supremepharmaceuticals.com

(TSXV:SL)
過去株価チャート
から 6 2024 まで 7 2024